Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies

Documenti analoghi

• Benefit–risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia
  di: Levitan, Bennett, et al.
  Pubblicazione: (2016)
• Are the Long-Acting Intramuscular Formulations of Risperidone or Paliperidone Palmitate Associated with Post-Injection Delirium/Sedation Syndrome? An Assessment of Safety Databases
  di: Alphs, Larry, et al.
  Pubblicazione: (2011)
• PM386. An Assessment of Injection Site Reactions and Injection Site Pain of Once-Every One Month and Three-Month Long-Acting Injectable Formulations of Paliperidone Palmitate
  di: Elefant, Erica, et al.
  Pubblicazione: (2016)
• SA12. Baseline Demographics and Clinical Characteristics From a Prospective, Randomized, Open-Label Study of Paliperidone Palmitate Long-Acting Injection in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder
  di: Brown, Brianne, et al.
  Pubblicazione: (2017)
• Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
  di: Sliwa, Jennifer Kern, et al.
  Pubblicazione: (2012)